Drugs / DOTA-ANTI-CEA antibody
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06395337 | May 2024 → May 2025 | malignant pancreatic neoplasm, rectal cancer | Radboud University Medical Center | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DOTA-ANTI-CEA antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06395337 ↗ |
| Modality | Protein / enzyme biologic | “dual-labeled Anti-CEA Antibody” NCT06395337 ↗ |
| Route | Intravenous | “single intravenous dose” NCT06395337 ↗ |